EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in Covalent Drug Discovery

Daniel Schaefer, Xinlai Cheng iD

Pharmaceuticals · 28.04.2023 · 16 (5) · 663

DOI: 10.3390/ph16050663 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 28.04.2023. Verfasst von Daniel Schaefer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Buchmann Institute for Molecular Life Sciences, Chemical Biology, Goethe University Frankfurt am Main, Max-von-Laue-Strasse 15. R. 3.652, 60438 Frank…. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Federal Ministry of Education and Research, the Hessen State Ministry of Higher Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In spite of the increasing number of biologics license applications, the development of covalent inhibitors is still a growing field within drug discovery. The successful approval of some covalent protein kinase inhibitors, such as ibrutinib (BTK covalent inhibitor) and dacomitinib (EGFR covalent inhibitor), and the very recent discovery of covalent inhibitors for viral proteases, such as boceprevir, narlaprevir, and nirmatrelvir, represent a new milestone in covalent drug development. Generally, the formation of covalent bonds that target proteins can offer drugs diverse advantages in terms of target selectivity, drug resistance, and administration concentration. The most important factor for covalent inhibitors is the electrophile (warhead), which dictates selectivity, reactivity, and the type of protein binding (i.e., reversible or irreversible) and can be modified/optimized through rational designs. Furthermore, covalent inhibitors are becoming more and more common in proteolysis, targeting chimeras (PROTACs) for degrading proteins, including those that are currently considered to be ‘undruggable’. The aim of this review is to highlight the current state of covalent inhibitor development, including a short historical overview and some examples of applications of PROTAC technologies and treatment of the SARS-CoV-2 virus.

Schlagwörter

Stichwörter der Autor:innen

COVID-19PROTACscovalent inhibitorsdrug designdrug discovery

Autor:innen und Institutionen

  • Buchmann Institute for Molecular Life Sciences, Chemical Biology, Goethe University Frankfurt am Main, Max-von-Laue-Strasse 15. R. 3.652, 60438 Frankfurt am Main, Germany.
  • Pharmaceutical Chemistry, Goethe University Frankfurt am Main, 60438 Frankfurt am Main, Germany.
  • Frankfurt Cancer Institute, 60596 Frankfurt am Main, Germany.

ORCID-Profile: Xinlai Cheng

Förderung

  • Deutsche Forschungsgemeinschaft
  • Federal Ministry of Education and Research
  • the Hessen State Ministry of Higher Education
  • DFG grant program
  • PROXIDRUGS
  • LOEWE Center Frankfurt Cancer Institute (FCI)

Zitieren

APA

Schaefer, D., & Cheng, X. (2023). Recent Advances in Covalent Drug Discovery. Pharmaceuticals, 16(5), 663. https://doi.org/10.3390/ph16050663

Vancouver

Schaefer D, Cheng X. Recent Advances in Covalent Drug Discovery. Pharmaceuticals. 2023;16(5):663. doi:10.3390/ph16050663

BibTeX
@article{Schaefer2023,
  author = {Schaefer, Daniel and Cheng, Xinlai},
  title = {Recent Advances in Covalent Drug Discovery},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {5},
  pages = {663},
  doi = {10.3390/ph16050663}
}
Kostenlos starten →